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The British Market for Medicine in the late
Nineteenth Century: The Innovative Impact of
S M Burroughs & Co
ROY CHURCH*
Historians of medicine have tended to be preoccupied primarily with scientific research,
the development of therapeutically significant medicines, and ethical business practice.
Roy Porter, however, adopted a wider conception. Referring to the eighteenth and early
nineteenth century, he redefined the role of ‘‘the vile race of quacks’’ (so described by their
own contemporaries
1) as a manifestation of a burgeoning medical entrepreneurship in an
emerging consumer society.
2 He maintained that ‘‘Irregular medicine ...mobilised the
growth of medicine as business’’,
3 an aspect of medical history which he believed to have
been largely ignored hitherto and one which requires of historians an understanding of the
market for pharmaceuticals.
4 Anne Digby has examined the market for medical services
during the nineteenth century in an analysis of interactions between doctors and patients at
a time when self-dosing was prevalent.
5 However, interactions between medical practi-
tioners and suppliers of medicines in Britain for most of this period remain largely
unexplored (with the significant exception of the work by Jonathan Liebenau
6) and as
a result, it will be argued, have been misunderstood.
# Roy Church 2005
*Roy Church, Emeritus Professor, University of East
Anglia, School of History, Norwich NR4 7TJ, UK.
The research on which this article is based was
funded by the Wellcome Trust as part of a joint project
with Dr Tilli Tansey to write the history of
Burroughs Wellcome & Co. I am glad to express my
gratitude to the Trust, and to others who have
helpedinvariouswaysinthepreparationofthisarticle:
Judy Burg, Steve Cherry, Julia Sheppard, Tilli Tansey,
and two anonymous referees. None is responsible
for the arguments presented here.
Much material used in this article is located in the
archives of the Wellcome Foundation held in
the Wellcome Library, London. These consist of
the personal letter books of Henry Wellcome
(WF/E/01/01, WF/E/01/02), of Silas Burroughs
(WF/E/02/05/01–02)), his private papers (PP/SMB)
and the records of Burroughs Wellcome & Co/The
Wellcome Foundation (WFA). At the time of going
to press, most of the material consulted was still
being catalogued and was not, therefore, available
to the public.
1John Forbes, ‘On the patronage of quacks and
imposters by the upper classes of society’, British
and Foreign Medical Review, 1846, 21: 533–40,
p. 533.
2Roy Porter, Quacks: fakers and charlatans in
English medicine, Stroud, Tempus, 2000, ch. 2.
3Roy Porter, ‘Before the fringe: ‘‘quackery’’ and
the eighteenth-century medical market’, in R Cooter
(ed.), Studies in the history of alternative medicine,
Basingstoke, Macmillan, 1988, pp. 1–27, on p. 19.
4Porter, op. cit., note 2 above, p. 285;
Roy Porter and Dorothy Porter, ‘The rise of the
English drug industry: the role of Thomas Corbyn’, in
Jonathan Liebenau, G J Higby, and E C Stroud (eds),
Pill peddlers: essays in the history of the
pharmaceutical industry, new series, No. 13,
Wisconsin, American Institute for the History of
Pharmacy, 1990, pp. 5–28. Elsewhere Roy Porter
observed that a ‘‘historical study of the roots of the
pharmaceutical industry is sorely needed’’, op. cit.,
note 3 above, p. 11.
5Anne Digby, Making a medical living: doctors
and patients in the English market for medicine,
1720–1911, Cambridge University Press, 1994.
6Jonathan Liebenau, ‘Marketing high technology:
educating physicians to use innovative medicines’,
in R P Davenport Hines (ed.), Markets and bagmen:
studies in the history of marketing and British
281This article examines pharmaceutical products and marketing innovations in the late
nineteenth century and explores the ensuing transition in the relations between medical
practitioners and suppliers of medicine. Such developments are set against the contextual
themes of progress in medical science and the treatment of illness in the period.
A perceived conjuncture between changing marketing methods and the development of
a science-based pharmaceutical industry in Britain led Liebenau to conclude that increas-
ing scientific complexity explained marketing innovation. He believed that, from the mid-
1890s, the ever more technical and scientific character of the new biological therapeutics
requiredtheadditionofan‘‘educationalfunction’’inmarketingwhichwouldtaketheform
of American style ‘‘detail men’’, who, in addition to calling on chemists and druggists,
visited doctors to explain and promote innovative medicines, preferably employing the
appropriate technical and scientific language.
7 The introduction of this practice in Britain
he attributed to Henry S Wellcome,
8 partner in Burroughs Wellcome & Co (BW&Co)
from1880who,inthemid-1890s,pioneeredthedevelopmentandproductionofanti-toxins
in Britain.
9
Liebenau’s strong association between science and technology and the marketing of
medicine is plausible as a rational narrative. However, subsequent research into the devel-
opment of the market for medicine in relation to medical reform, the nature of medical
science in the nineteenth century, and the history of the predecessor company of
S M Burroughs & Co (SMB&Co) suggests that the interpretation is open to question.
Placed within the emergence of the contemporary market for medicine, the test conducted
here focuses on the contributions made by Silas Burroughs and the enterprise he estab-
lished after moving from Philadelphia to London in 1878. Historians have concentrated on
their successors, Henry Wellcome and BW&Co, probably because from 1895 Wellcome
wasthesolesurvivingpartnerofthelattercompanyuntilhisdeathin1936.Thesignificance
of Silas Burroughs’s predecessor company, however, lies not in historians’ neglect of its
briefexistence,butintheimportantcontributionBurroughsmadeinestablishinginnovative
marketing foundations for a modern pharmaceutical industry in Britain. Within months of
BW&Co’s trading in Britain, the Medical Press and Circular had praised the company’s
success in introducing innovative American products through a novel approach to market-
ing drugs.
10 On the opening of a large factory at Dartford in 1888, the firm of BW&Co was
referred to by a reporter in the Chemist and Druggist as ‘‘an exponent of modern phar-
macy’’, which, through distinctive advertising and promotion had created‘‘an entirely new
classofbusiness’’andestablisheda‘‘world-widereputation...withinthelasttenyears’’.
11
industrialperformance,1830–1939,Aldershot,Gower,
1986, pp. 82–101. This study grew out of Liebenau’s
primary research into the history of the American
pharmaceutical industry, the subject of Medical
science and medical industry: the formation of the
American pharmaceutical industry, Basingstoke,
Macmillan, 1987.
7Liebenau, ‘Marketing high technology’, op. cit.,
note 6 above.
8Ibid., p. 91.
9Almost certainly, Burroughs Wellcome & Co
became the largest and indisputably the leading
pharmaceutical manufacturer in Britain by 1914,
the first to establish laboratories employing
scientists of the highest calibre, who conducted
pure research in addition to contributing to the
company’s commercial success. For an introduction
to the history of BW&Co and a portrayal of
the two partners, see Robert Rhodes James,
Henry Wellcome, Hodder & Stoughton,
1994.
10Med. Press Circular, 3 Aug. 1881.
11Chem. Drug., 28 Jan. 1888, 32: 104–6.
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Roy ChurchSignificantly, the reference to ‘‘ten years’’ included the period when SMB&Co was in
business. The other justification for examining the company’s history is that it provides
evidenceagainstwhich Liebenau’sinterpretationoftherelationshipbetweenmedicine and
marketing during the late nineteenth century can be tested.
The Nineteenth-Century Market for Medicine:
Narrative and Interpretation
The characteristics of the market for medicine into which Burroughs sought to introduce
innovative American medical goods were those of expansion and competition. Expansion
was partly a consequence of a long-term rise in real incomes begun in the eighteenth
century. Substantial falls in commodity and wholesale prices occurred in the 1870s and
1880s and contributed to increasing purchasing power.12 Falling drug prices imposed a
downward pressure on profit margins which competition intensified.
13 Competition also
resulted from the emergence of rival groups, each possessing an interest in stimulating the
demand for medicine and in so doing contributing to the medicalization of society. First,
the apothecaries spearheaded the drive to sell drugs. Chemists and druggists, whose
numbers, it is estimated, increased fourfold between 1865 and 1905—from something
over 10,000 to more than 40,000
14—added to the momentum by selling drugs over the
counter to meet demand generated by self-medication. Those chemists who could afford to
avoid stocking patent or proprietary medicines, for which increasingly extravagant claims
were vigorously advertised,
15 formed a recognizable e ´lite in the trade, the core of an
aspiring profession. They were aided by the growing numbers of wholesaler–
manufacturers who, by expanding the supply and range of ingredients, facilitated retailers’
abilitytomakeuptheirownpreparations.Theretailers’tacticwastoconcentrateonselling
at lower prices those orthodox medicines which medical practitioners dispensed at sub-
stantial profit to themselves.
16 However, commercial pressures compelled most chemists
to stock a wider range of medications and toiletries. These extended to patent and pro-
prietary medicines such as Eno’s Fruit Salt for bile-laden blood, Mother Siegal’s Curative
Syrup for unspecified stomach ailments, and Beecham’s pills. The ingredients of such
proprietary medicines were secret, their trade names protected by law from 1875, and they
were heavily advertised as cures for numerous conditions.
17 Both the medical profession
and suppliers of drugs or pharmaceuticals disapproved of such products.
12C H Feinstein, ‘A new look at the cost of living,
1870–1914’, in James Foreman-Peck (ed.), New
perspectives on the late Victorian economy: essays
in quantitative economic history 1860–1914,
Cambridge University Press, 1991, pp. 151–79.
13Stanley Chapman, Jesse Boot of Boots the
chemists, London, Hodder & Stoughton, 1974, p. 26.
14Ibid.
15Hilary Marland, ‘The medical activities of
mid-nineteenth-century chemists and druggists, with
special reference to Wakefield and Huddersfield’,
Med. Hist., 1987, 31: 415–39; S W F Holloway,
‘The orthodox fringe: the origins of the Royal
PharmaceuticalSocietyofGreatBritain’,inWFBynum
and R Porter (eds), Medical fringe and medical
orthodoxy, 1750–1850, London, Croom Helm, 1988,
pp. 129–35; S F W Holloway, ‘Cutting remarks:
reflections on the origins of the Proprietary Trade
Association’, Pharm. J., 1996, 256: 198–9.
16Marland, op. cit., note 15 above, pp. 418–39.
See also A McAuley Brownfield-Pope, ‘From
chemist shop to community pharmacy: wide study
of retailing chemists and druggists, c.1880–1960’,
PhD thesis, University of East Anglia, 2003,
chaps. 1–3.
17In 1808, a Nottingham chemist sold more
than 200lbs of opium and 600 pints of Godfrey’s
Cordial to the local poor. Roy Porter, ‘Death and the
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The Innovative Impact of S M Burroughs & CoSimilar diversity in business practice was evident among medical practitioners who,
like chemists and druggists, belonged to an over-supplied occupation in which many
struggled to survive.
18 Those reduced to becoming ‘‘sixpenny doctors’’, selling drugs
and bottles of medicine for 6d and handing back change in cash bore a ‘‘degrading
stigma of trade’’.
19 Others had to sacrifice their independence in clinical practice in
order to make a medical living by serving friendly societies, clubs, or poor law institu-
tions. The e ´lite among physicians fulfilled their role as consultants in the growing
number of hospitals; those in London, for whom private patients continued to be a
lucrative source, enjoying the highest status and incomes.
20 Symptomatic of efforts to
fulfil rising aspirations through demarcation between the various groups were the
Apothecaries Act of 1815, the establishment of the Pharmaceutical Society in 1840
and of the British Medical Association in 1856, the 1858 Medical Act, and the Pharmacy
Act of 1868.
21
The characteristic products bought and sold in the market for medicine reflected the
persistence of a traditional emphasis on the use of drugs to restore a healthy balance. The
regulation of air, food, drink, sleep, and lifestyle were central to recommended regimes.
22
Dietetic food, therefore, fell well within the contemporary definition of medicine. At the
other end of the spectrum, by the late nineteenth century, the category of science-based
therapeutics was emerging. The use of the term ‘‘science’’ by doctors to distinguish
between the practices of medical practitioners and other healers had begun early in the
century.
23 It could be linked to the application of new ideas and techniques applied in
hospitals, even though competing views as to the definition of ‘‘science’’ persisted.
24
The consultants who dominated hospital practice by the late nineteenth century often
regarded treatment as experimental before prescribing for their lucrative private patients.
Not all consultants were specialists, many acted as generalists, basing their reputation as
much on their gentlemanly status as on their scientific knowledge. They were as much
susceptible to fads and fashions as doctors working in humbler circumstances. However,
for physicians of all classes, the notion of diagnosis and the prescription of drugs appeared
doctors in Georgian England’, in R Houlbrooke (ed.),
Death, ritual and bereavement, London, Routledge,
1989, p. 93. Bile beans were advertised as applicable
to 38 ailments and Beecham’s pills to 31. Thomas
Richards, The commodity culture of Victorian Britain:
advertising and spectacle, 1851–1914, London,
Verso, 1991, p. 180. Sales of patent medicines are
estimated to have risen from £0.5m in the mid
nineteenth century to £4m by 1900. Chapman, op. cit.,
note 13 above, pp. 22–3.
18Anne Digby, The evolution of British general
practice, 1850–1948, Oxford University Press,
1999, p. 101.
19Irvine Loudon, ‘Medical practitioners,
1750–1850, and the period of medical reform’, in
Andrew Wear (ed.), Medicine in society, Cambridge
University Press, 1992, pp. 219–47, on p. 241.
20Lindsay Granshaw, ‘The rise of the modern
hospital in Britain’, in Wear (ed.), op. cit.,
note 19 above, pp. 197–218, on pp. 205–9.
21S W F Holloway, Royal Pharmaceutical
Society of Great Britain: a political and social
history, London, Pharmaceutical Press, 1991,
pp. 240–61.
22Christopher Lawrence, ‘Incommunicable
knowledge: science, technology, and the clinical
art in Britain, 1850–1914’, J. Contemp. Hist., 1985,
20: 504–12; Michael Worboys, Spreading germs:
disease theories and medical practice in Britain,
1865–1900, Cambridge University Press, 2000,
pp. 284–9.
23John Harley Warner, ‘The idea of science in
English medicine: the ‘‘decline of science’’ and the
rhetoric of reform, 1815–1845’, in Roger French and
Andrew Wear (eds), British medicine in an age of
reform, London, Routledge, 1991, pp. 136–64,
on pp. 154–7.
24Christopher Lawrence, Medicine in the
making of modern Britain, 1700–1920, London,
Routledge, 1994, pp. 38, 72.
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Roy Churchto be a more focused approach and less time-consuming than the regimens typically
advocated by traditional physicians. These tended to be protracted, expensive, and
disagreeable.
25
Physicianswereinapowerfulpositiontodecidewhichmedicinesshouldbeemployedin
their hospitals and in the growing number of other institutions that engaged their services,
an increasingly important dimension of the market. The payment of physicians for med-
icine declined during the century,
26 but for consultants and general practitioners alike,
compensation could be sought through their role as sources of prescriptions and advice. By
prescribing the use of the medical products they favoured, payment for repeated advice
became integral to the process of competing for patients and an alternative method of
generating income. Similar consideration regarding consumers’ satisfaction affected the
trading activity of chemists and druggists whose own preparations encountered increasing
competition from proprietary medicines.
27
When Burroughs set up his business in London in June 1878, he confronted a market
which exhibited contrasting characteristics. At one end, chemists and druggists were
expanding the scope for self-doctoring and dosage; at the other, even though the literature
of medical science itself was fiercely contested,
28 consultants and the e ´lite among general
practitioners were advancing an association with science to bolster their positions in the
professional hierarchy, toenhance remuneration,and tosecure medical control.
29 In such a
complex, fluid market, opportunities existed for suppliers who could project an image of
scientific modernity for the products on sale. For example, one advertisement referred to
the preparationof a dietetic food, supplied to S M Burroughs & Co as the agent, to be taken
under the supervision of an experienced chemist.
30 Another referred to its manufacture on
Justus von Liebig’s principle, that the ‘‘restorative remedy’’ was listed in the German
Pharmacopoeia, and that the product had yet to be introduced in England on an appreciable
scale.
31 Market opportunities also existed for those offering products which appealed to
consumers as more acceptable than those hitherto available, for medications that were
palatable, moreeasily administered, andwhich affectedbodilyfunctionstoalesser degree.
Traditional homeopathy offered such an alternative. Burroughs, however, sought to pro-
motethenovelAmericanproductsheintroducedasthoroughlymodern,submittingthemto
the Lancet for testing and report in a regular column entitled ‘New inventions’.
32 The
association of products with a scientific approach in production and modernity in form
were additional elements in the marketing strategy introduced to England by Silas
Burroughs in 1878.
25Porter, op. cit., note 3 above, p. 4; idem, op. cit.,
note 2 above, pp. 204, 206.
26Holloway, ‘The orthodox fringe’, op. cit.,
note 15 above, p. 154.
27E M Tansey, ‘Pills, profits, and propriety: the
earlypharmaceuticalindustryinBritain’,Pharm.Hist.,
1995, 25: 3–9, p. 3; see also Roy Porter, Health for
sale: quackery in England 1660–1850, Manchester
University Press, 1989.
28Worboys, op. cit., note 22 above, pp. 284–9.
29Lawrence, op. cit., note 24 above, pp. 75–8.
30Chem. Drug., 15 Feb. 1879, 21: 63.
31Ibid., 14 June 1879, p. 5. Burroughs wrote
to the editor of the Medical Times and Gazette,
enclosing a sample product submitted for
examination, testing, and a report in the journal.
He expressed the wish that the report should
include a reference to the favourable opinion on
the company’s products by Dr Roberts when
addressing a meeting of the Lancashire and
Cheshire branch of the BMA. WF/E/02/05/02,
25 July 1879.
32Medical Times and Gazette, 10 Oct. 1879.
See also footnote 34 below.
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The Innovative Impact of S M Burroughs & CoThe Formation and Development of S M Burroughs & Co
To offer an alternative account of this process, it is necessary to focus on the firm of
SMB&Co. Following a series of positions as clerk and counter-salesman in drug stores
in the State of New York from the age of nineteen, Burroughs probably joined the small
Philadelphia drug-manufacturing firm of John Wyeth & Brother in 1869 when he was
twenty-three and travelled on the road as a detail man.
33 He studied at the Philadelphia
CollegeofPharmacyin1876–7,graduatingafterwritingathesisentitled‘Thecompression
of medicinal powders’.
34 The combination of the apprenticeship with the Wyeth brothers
and the opportunity at college to research a subject in depth proved to be a perfect
launching pad for Burroughs’s long-term career in the pharmaceutical industry. The
business experience of Frank Wyeth and the knowledge of John Wyeth (a Philadelphia
graduate pharmacist) provided further learning opportunities, especially because in 1872,
the brothers had patented the first American rotary press and had begun to manufacture
compressed pills in the following year.
35
Although this represented low technology, it remained for many years the basis of a
rapidly expanding trade in compressed medicines. In his ‘Inaugural essay’ (graduating
dissertation),Burroughsreviewedthehistory,stateoftheart,currentmethodsofproduction,
andtheextentofthepracticeofmakingcompressedmedicines.Heconsultedsources,citing
trialsandpublicationsfromtheUnitedStates,Germany,andBritain.
36Hepossessedexpert
knowledge, therefore, of the theory, manufacture, and history of all aspects of compressed
medicines.Hewasalsoaprovensuccessasadetailmansellingthenewproducts(medicinal
powdersintablet form,hypodermictablets, triturates,andmedicinal lozenges),which, like
virtually all similar products at the time, offered questionable medicinal value but were,
at least, harmless. Wellcome acknowledged this early in 1882, telling Burroughs, ‘‘No
chemist, no agent can place articles before the profession as intelligently as you can’’.
37
Burroughs’s flaws had barely begun to irk Wellcome at this time,though they were soon
to exasperate him. John Wyeth, however, had long before lost patience with his former
detail man. He regarded Burroughs as wayward in his approach to detailing, incurring
excessive costs in salary and expenses. He also entered into ill-considered commitments
with agents and exhibited a general resistance to managerial control. To distance them-
selves from the perceived flaws, yet wishing to exploit Burroughs’s undoubted knowledge
of the new compressed medicines, the Wyeth brothers offered Burroughs a sole overseas
agency to sell their products in Britain and Europe. This was a low cost arrangement
for the Wyeths. They thought that by visiting doctors and chemists and leaving samples
33On Silas Burroughs’s life, see G MacDonald,
Onehundredyears:Wellcome:inpursuitofexcellence,
London, Wellcome Foundation, 1980; John Davies,
‘Silas Burroughs, Part 1: The early years from
Medina to medicines’, Wellcome Journal, Feb. 1991:
10–11; Rhodes James, op. cit., note 9 above,
chs 3–5.
34University of the Sciences in Philadelphia,
College of Pharmacy Box, manila envelope and
S M Burroughs, ‘Inaugural Essay’, 1877. There is
some uncertainty regarding both the date when
Burroughs joined the Wyeths and the duration of
his studies. I am grateful to Julia Sheppard for this
information.
35Tom Mahoney, The merchants of life: an
account of the American pharmaceutical industry,
New York, Harper, 1959, p. 31.
36Davies, op. cit., note 33 above, pp. 10–11.
37However, his weaknesses were shortly to
frustrate Henry Wellcome, too. WF/E/03/01/01,
p. 32, H Wellcome to S M Burroughs, between
23 Jan. and 16 Feb. 1882.
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Roy Church(a practice they believed to be completely unknown in Britain), Burroughs would quickly
succeed, despite his faults, in creating a market for the new products.
38
Consequently, inthe springof1878,atthe ageofthirty-two, Burroughsleft Philadelphia
forLondon.Hisearlycontactswiththemedicalprofessionpromptedhischaracterizationof
‘‘the Englishman’’ as one who took time to convince, but who, ‘‘once convinced he stands
firmlyby the goodshe hasfound good’’.
39He set out toassure doctors of the uniqueselling
points of compressed medicines: ‘‘They are convenient, both to carry and to use; they are
accurate, enabling the physician to administer precisely the dose desired; and they are not
liabletochangebykeeping’’.Accurateallopathicdoserepresentedanadvanceintheability
to control medication; other qualities affecting ease of administration were of a more
cosmetic character, though from the standpoint of patients and chemists, they were a desir-
abledevelopment.
40Describingthecontributionsthebusinesshadmadetothedevelopment
ofthe trade, the company drewattentiontoitsintroductionof‘‘aprogressive pharmacy’’in
which reliability and accuracy based on a scientific approach to medicine were combined
withthepleasingcharacteristicsofhomeopathicmedicine.Theresultwastofreeconsumers
from the ‘‘nauseous and unsightly messes frequently compounded ...worse than the dis-
eases they were prescribed to cure’’.
41 Samples of the Wyeths’ chlorate of potash tablets,
chloride of ammonia, dialysed iron, and pepsin, as well as Parker’s lint were dispatched to
London hospital consultants. Their advantages were advocated during the visits that fol-
lowed; this was a unique approach in the trade at the time.
42 Believing that British doctors
associated compressed pills with American quackery, Burroughs claimed to be the first to
replacetheword‘‘pill’’withtheword‘‘tablet’’whichheregisteredasatrademarkin1878.
43
Making personal connections, establishing communications, and being persistent were
key elements in the new approach to marketing. Samples, free of charge, were sent to
consulting rooms in hospitals. Doctors were assured that stocks were available in the
dispensary for prescriptions to hospital patients.
44 Hospitals were regarded as the most
effective route through which to establish the credibility of preparations leading to
prescriptions for doctors’ private patients and sometimes to favourable publicity.
To Lennox Browne, FRCS, Burroughs wrote:
We beg to present the London Throat Hospital with a small quantity of our compressed Chlorate of
Potash and Chlorate of Potashwith Borax ...We shall be happy to donate a further supply of guineas
worth to the Hospital if you will see that they are made up and not thrown away as has been the case
with some other Hospitals to which we had made donations ...We feel much complimented in
reading your article in the Medical Times and Gazette that you should speak so kindly of the
compressed drugs ... We trust that you will not object to our quoting from your article in our
advertisements.
45
38WFA, Acc82/1 Box 15, J Wyeth to S M
Burroughs, 13 April 1881.
39WF/E/02/05/01, S M Burroughs to J Wyeth,
22 Oct. 1878.
40WFA, PB110, Medical formulae of new and
improved chemical preparations, 1881, p. 35. The
list and accompanying text refer to several products
supplied before 1880.
41Chem. Drug., 27 July 1895, 47: 91.
42WF/E/02/05/02, S M Burroughs to Romford
Chemical Co, 6 Nov. 1879.
43S M Burroughs to Chem. Drug., 28 May 1892,
40: 785.
44WF/E/02/05/01, S M Burroughs’s letters to
Middlesex, St Mary’s, and Paddington hospitals,
10, 12, 19 July 1878.
45WF/E/02/05/02, S M Burroughs to Lennox
Browne, 17 Oct. 1879.
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The Innovative Impact of S M Burroughs & CoFrom the beginning, advertising directed at medical professionals and chemists and
druggists was limited primarily to the Lancet, British Medical Journal, Medical
Press and Circular, Medical Times and Gazette, Chemist and Druggist, and to Price’s
Circular which commanded a wide international circulation. In this respect, Burroughs
adopted an ethicaladvertising policy. The distributionin September1879 of 2,500 sixteen-
page booklets describing products is indicative of the scale of operation.
46 Burroughs
sought to identify other potential customers through retailers prior to direct mailing. Thus,
in relation to his campaign to promote chlorate of potash tablets in 1879 he wrote to
Messrs Lowe & Co, chemists of Dumfries: ‘‘Not having received the promised list of
clergymen, lawyers, public speakers, & singers of your neighbourhood, we conclude
youmusthaveforgottenit,&begagaintocallyourattentiontoit,asamatterofimportance
to yourselves as much as to us.’’
47 John Wyeth disapproved of the volume of advertising
expenditure and accused Burroughs of suffering from ‘‘patent medicine impulses’’,
48
such as that displayed in the marketing of chlorate of potash tablets, as effective in
clearing ‘‘a husky voice ...as by magic in the course of a few minutes’’.
49 Alfred Bishop’s
granular effervescence citrate of caffeine, advertised as ‘‘the best known remedy for head-
aches’’ was another example, although the British Medical Journal reported after testing,
‘‘We have administered it in nervous headaches and in the malaise following an alcoholic
debauche with benefit’’.
50 The sale of Nubian Waterproof Blacking (widely advertised
as ‘‘THE NEW DISCOVERY. A profitable addition to a druggist’s business’’)
51 took
Burroughs even further from the ethical medicine business. Wyeth urged Burroughs to
stick to visiting physicians to offer them samples.
52 Burroughs defended his advertising
policy by explaining that British doctors paid more attention to journals (which charged
higher fees than in the US) and that editors wrote good notices relating to their advertisers.
These, in turn, provided useful quotations for inclusion in trade circulars.
53
The recruitment of commercial travellers to share the burden and to create a market
outside London proved to be problematic. Burroughs told the Wyeths, ‘‘It is almost impos-
sible in this country, the commercial traveller is a stereotyped man. Men who can do what
we want are not to be had and would be too expensive even if we could find them; we
are, therefore, doing it ourselves’’.
54 Without false modesty, Burroughs advertised for
‘‘one or two medical gentlemen (who would like to assist the leading men in the profession
in the principal towns in England and Ireland) to introduce a new pharmaceutical prepara-
tion [Chlorate of Potash] and surgical appliance of much merit and interest’’.
55
46Ibid., Order, 23 Sept. 1879.
47S M Burroughs to Lowe & Co, 6 May 1879,
quoted in Rhodes James, op. cit. note 9 above,
p. 75, note 31.
48WFA, Acc82/1 Box 15, J Wyeth to
S M Burroughs, 13 Apr. 1881.
49Chem. Drug., 15 Dec. 1885, 27: 97.
50WF/M/GB/08/01,clippingsofBW&Coadsfrom
Br. med. J., Book 1, 1880.
51Chem. Drug., 15 March 1879, 21: 63.
52WFA, Acc82/1 Box 15, J Wyeth to
S M Burroughs, 13 Apr. 1881.
53WFA, Acc82/1 Box 15, J Wyeth to H Wellcome,
9 July 1880; WF/E/02/05/01, S M Burroughs to
J Wyeth, 22 Oct. 1878.
54WF/E/02/05/01, S M Burroughs to J Wyeth,
13, 19 Aug. 1878.
55WF/E/02/05/01, draft advertisement for the
Lancet, 29 Sept. 1879. The ‘‘pharmaceutical
preparation’’ was to alleviate bronchial irritation and
hoarseness. It was advertised as especially
convenient for singers and public speakers, including
clerics. The appliance referred to was probably the
Silas Burroughs Ammonia Inhaler, described in a
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Roy ChurchC Stanley Churton was appointed as commission agent to call on medical men and
chemists. The terms were 20 per cent commission on orders from the former (‘‘knowing
that calling on medical men is time-consuming’’) and 15 per cent on chemists’ direct
orders.
56Asimilaradvertisementwasdirectedatpharmacists.
57InMarch1879,Burroughs
reported that five travellers were constantly on the road.
58
Burroughs’s approach to chemists and druggists was aimed at encouraging them to seek
orders from their existing doctor clientele and sometimes included special inducements.
For example, he wrote to Messrs J & H Smith, ‘‘We have pleasure in presenting to your
Medical Friend specimens of [etc. etc.]. If he should see fit to order those articles through
you we will in addition to our lowest prices, donate to his Hospital 1/3 as much as the order
amounts to’’.
59 Samples, wrapped to display the chemist’s own name, were distributed to
the homes of medical men (located through a directory) within the district served by the
chemist. Letters informed each physician that his local chemist had supplies of the sample
goods in stock. At the same time, chemists were encouraged to advertise using counter
displays,
60 a method of reinforcing the promotion to customers.
A similar pincer movement, directed simultaneously at professionals and trades people,
involved expert endorsements, another dimension of Burroughs’s marketing strategy. The
firm of Claudius Ash & Son, dental wholesalers in London, was believed to be insuffi-
cientlyvigorousinpushingLawton’sAbsorbentCotton(‘‘whiter,freefromcontamination,
most absorbent of its kind’’), a product popular in the US. Burroughs supplied more
specimens which bore the wholesaler’s name on the wrapper indicating the wholesaler’s
status as an agent. He also undertook to obtain recommendations ‘‘from one or two leading
men in the dental profession’’.
61 One eminent London surgeon was so impressed by a
sampleofthecottonthat,accordingtoBurroughs,healsoseemedwillingtoendorseitfully
andgivehisnametoitas ‘‘Bryant’s AbsorbentCotton’’.‘‘His namewill beofgreatservice
in introducing it to medical professionals in this and other countries, and he will assist us
considerably, we believe, by mentioning it in his books’’.
62 Endorsements were inserted
into diaries such as the Physicians and surgeons memorandum book (September 1879),
which Burroughs issued to medical men.
63
In the expectation that fluid extracts would be increasingly profitable, Burroughs
arranged for the Wyeths to supply a range of these, including jasmine, dock, and
sarsaparilla.
64 A significant next step was the advertisement of a range of items having
trademarks registered under his own name: Silas Burroughs’s Bromide of Potassium and
Calisaya Bark Elixirs, Dextra Quinine, Pepsin, and Hazeline.
65 His introduction of
quotation from the Lancet as ‘‘an ingenious and
convenient device’’, which was claimed to remove
catarrh and render the patient ‘‘less susceptible to the
weather’’. WFA, PB110, Medical formulae, op. cit.,
note 40 above, p. 39.
56WF/E/02/05/01, S M Burroughs to C Stanley
Churton, 9 Oct. 1878.
57WF/E/02/05/01, draft advertisement,
29 Sept. 1879.
58WF/E/02/05/02, S M Burroughs to L W Warner
& Co., NY, 18 March 1879.
59Ibid., S M Burroughs to J & H Smith,
15 Oct. 1879.
60Ibid., S M Burroughs to Heander & Riches,
20 March, 1879.
61Ibid.,SMBurroughstoAsh&Son,3Sept.1879.
62Ibid., S M Burroughs to J Wyeth, 8 May 1879.
63Davies, op. cit., note 33 above, p.13.
64Annual sales of between £4,000 and £5,000
were described as ‘‘very large.’’ WF/E/02/05/01,
S M Burroughs to J Wyeth, 11 July, 15 Aug. 1878.
65WF/E/02/05/02, S M Burroughs to J Wyeth,
26 Oct. 1878.
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The Innovative Impact of S M Burroughs & CoSilas Burroughs’s Beef and Iron Wine (improved) ‘‘A HIGHLY CONCENTRATED
STRENGTH GIVING FOOD TONIC’’ in the spring of 1880, offended the Wyeths
who regarded it as being in competition with their own Beef and Iron Juice. None
the less, Burroughs refused their proposal that he should purchase the superior
Wyeth formula ‘‘at cost’’, while the Wyeths supplied the beef and iron solution to
which wine could be added in London.
66 Under the terms of their agreement, Burroughs
had the option of acting as agent for other firms’ products which did not compete
with theirs.
Agency agreements proliferated. Among the first in 1878, was an agency for Nubian
Waterproof Blacking,
67 a product that was supplied to Burroughs by the Blake &
Goodyear Boot and Shoe Machinery Co and sold through chemists.
68 Within a
year, he claimed to have succeeded in selling blacking to a majority of co-operative
societies.
69 However, most agencies he acquired were for remedies, tonics, elixirs, and
health foods. American trademarked preparations registered under Burroughs’s name as
sole agent included Professor Horsford’s Acid Phosphate (presented by the makers as a
remedy for physical exhaustion, headaches, and stomach disorders),
70 and Fellowes
Medical Manufacturing Co’s compound syrup and hypophosphates (a popular all-pur-
pose remedy).
71 From the London Manufacturing Co in New York, Burroughs secured
supplies of Starr’s Extract of Beef to sell in cans in a rapidly growing but increasingly
competitive market, an initiative which, by March 1879, had convinced Burroughs of
the imperative to brand items in order to confer speciality status.
72 Burroughs’s Haze-
line (an extract of witch hazel) was one of the first. Among this varied product range,
although Wyeth’s compressed medicines consisted essentially of formulations of exist-
ing products, because of the form they took and the advantages in administration which
they offered these innovative products proved to be the most successful in the British
market for medicine.
The Acquisition of the Kepler Malt Extract Company
Dietetic food was to become a leading product of BW&Co. The product originated in
December 1878, when Burroughs was party to an agreement to form the Kepler Malt
Extract Company (KMEC). The purpose was to exploit the English patents for the
formulae and for the mashing apparatus to make a dietetic preparation from a mixture
66WFA, Acc82/1 Box 15, J Wyeth to
S M Burroughs, 13 April 1881; WFA, PB110,
Medical formulae, op. cit., note 40 above.
67Chem. Drug., 15 March 1879, 21: 63.
68Rhodes James claimed that Kepler Malt
Extract was the first British product to be added to the
Silas Burroughs line, but the association with
Nubian Blacking Co preceded this. Rhodes James,
op. cit., note 9 above, p. 77. WF/E/02/05/01, T Y Kelly
to S M Burroughs, 16 Sept. 1878; WFA, Acc99/6/7,
Memorandum of Association, Jan., 1881, which
refers to the original agreement including Silas
Burroughs in December 1878. Evidence of
selling Kepler occurs in March 1879.
WF/E/02/05/02, S M Burroughs to Alfred Lewis,
4 March 1879.
69WF/E/02/05/01, T Y Kelly to S M Burroughs,
16 Sept. 1878; 3 Sept. 1879.
70WFA, Acc85/16, Trade Marks, Silas Burroughs
& Co. The substance was later found to contain
fluorine, a poisonous or deleterious ingredient. This
verdict appeared in Journal of American Medicine,
1939, 113 (1): 78.
71WFA, Acc85/16, Trade Marks, Silas
Burroughs & Co.
72WF/E/02/05/02, S M Burroughs to London
Manufacturing Co. NY, 18 March 1879, p. 95:
‘‘[request substitute] ‘keep in a cool place’ for
‘keep on ice’ as ice is not plentiful here in
summer’’; 23 Sept. 1879; 7 May 1879.
S M Burroughs to Wans & Son, 2 May,
22 Sept. 23 Sept. 1879.
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Roy Churchof cod liver oil, glycerine spirit or alcohol, and malt from which variant combinations
could be produced.
73 His connection with this project began after an approach by
Philip Lockwood, owner of a patent for a malt extract. Lockwood was also chairman
of the Condensed Beer Company located in Jersey, whence malt was supplied to KMEC.
Burroughs was invited to become managing director of KMEC and he used his own
London premises for mixing, bottling, and ‘‘putting up’’ (labelling and packing) the cod
liver oil and malt extract ready for sale, as well as for marketing the new dietetic
preparation. When the enterprise was registered as a joint stock company at the Russell
Street office in January 1879,
74 Burroughs held shares valued at £1,000 which represented
almost 50 per cent of paid-up capital.
75 In addition to dividends, Burroughs was to receive
5 per cent on sales for his management services paid from Lockwood’s royalties, the
patent on Lockwood’s ‘‘secret process’’ having passed to KMEC.
76 Within two years,
Burroughs had masterminded the acquisition of the company. This included the trans-
ference of Lockwood’s patent and trademark to the ownership of BW&Co, an acrimo-
nious transaction, the final details of which were left to Wellcome to negotiate during
Burroughs’s absence overseas.
The connection between Burroughs and malt extract was not serendipitous. As early
as July 1878, he had asked John Wyeth to secure for him a sole agency of some first
class malt extracts from the US for selling in Britain, ‘‘We are satisfied it will take[?]
here and if we don’t ... somebody else will ... We want fluids or extracts if there is
money in them.’’
77 It seems that the technical chemist at Allen & Hanburys thought
along similar lines, enabling the company in 1879 to commence the manufacture of malt
extract, by his patent method of extraction using a vacuum which was claimed by the
company to be the first in Britain.
78 For some years, malted grain extract, condensed and
mixed with castor or cod liver oil, had become established as a nutritive and restorative
remedy and was listed in the German Pharmacopoeia. In the US, too, where Burroughs
appears to have possessed some experience of researching if not selling malt extract,
79 it
had begun to compete with cod liver oil, which had long been employed in Britain and
Continental Europe as a treatment for phthisis and other wasting diseases, and as a
remedy for defective nutrition.
80 The objectionable taste and pungent odour of cod liver
oil had been reduced during the 1870s by the steam process, invented and widely
adopted in Norway, but even the processed oil could still cause nausea.
81 Malt extract,
however, not only further disguised the objectionable characteristics of cod liver oil but
could also be used alone or with other drugs, for example, quinine, pepsin, or iron for
the sake of the digestive value of pure malt extract.
82 When KMEC began to produce
what the Commissioner Patents Journal recorded as ‘‘an invention of new or improved
73WFA, Acc99/6/7, Memorandum of Association.
20 Oct. 1879.
74Ibid.
75WFA, Acc99/6/7, Memorandum of Association,
22 Oct. 1879.
76WFA, Acc99/6/7, P Lockwood to BW&Co.
22 Oct. 1879, 9 April 1881.
77WF/E/02/05/01, S M Burroughs to J Wyeth,
11 July 1878.
78Geoffrey Tweedale, At the sign of the plough:
275 years of Allen & Hanburys and the British
pharmaceutical industry, 1715–1990, London,
John Murray, 1990, pp. 78–9.
79WFA, Acc99/6/7, P Lockwood to J Wyeth,
28 Aug. 1879.
80WFA, Acc82/1, Box 21: Chem. Drug.,
15 Feb. 1879, 21: 13; 15 July 1879, 21: 23.
81F Peckel Mo ¨ller, Cod-liver oil and chemistry,
London and Christiana, P Mo ¨ller, 1895, pp. v–vi,
lvi–lvii.
82H A Phillips, ‘Winter time is Kepler time’,
Foundation News, 2 (Oct. 1952), pp. 6–8.
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83 malt extracts had not, hitherto, been widely introduced in
Britain.
84 This had changed when American and German companies began to advertise
products similar to Kepler Malt Extract in the Chemist and Druggist and in British
medical journals. The Kepler initiative gave Burroughs the opportunity to be among the
innovators in the emerging dietetic market. His high expectations regarding a market
trend were to be fulfilled both nationally and across the world. The vigorously
promoted Kepler extracts, one of the strongest international brands until the 1930s,
contributed to this.
Burroughs adopted an approach to marketing Kepler extracts identical to that applied to
compressed medicines and other preparations. This consisted of the canvassing of che-
mists and druggists, visits to doctors and offers of special discounts or hospital donations
in kind, ethical journal advertising, and the appointment of agents, usually on a 10 per cent
commission.
85 An advertisement in the Chemist and Druggist in February 1879,
announced the sale of ‘‘improved Malt extract ...containing all the valuable Nutritive
and Digestive Properties of the Best Malted Barley, Wheat and Oats concentrated in
vacuo. FREE FROM ALCOHOL. Possesses from five to ten times more value than any
Alcoholic or Fermented Extract of Malt.’’ Justus von Liebig was quoted as an author-
itative support for the claim of the muscular and fat-producing elements contained in
wheat and oats, and for the assertion that malt was rich in diastase. The advertisement,
directed especially at hospitals and surgeons, referred to the company chemist’s twenty
years’ experience ensuring that the ‘‘new and improved’’ process of malt extraction under
his supervision produced a high quality product.
86 Where Wyeth’s goods were thought to
compete with Kepler extracts, Burroughs pushed the latter. He told his Dublin agent,
We believe ... that ‘‘Kepler’’ goods will meet with a more ready sale in your market than the
articles introduced from Messrs J. Wyeth & Bro ...We are advertising regularly in the Medical
Press and Circular and as they have given the goods favourable notices to other preparations of
malt we trust they will make this notice as strong as possible.
87
Burroughs was relentless in seeking favourable publicity for the new product. When
samples of Kepler extracts, sent to the editor of the Medical Times and Gazette for testing,
appeared to have been overlooked, Burroughs wrote to him offering more, ‘‘in order to
examine them sufficiently to warrant a notice of them in your journal’’.
88 Offering to
supply any quantity requested for hospital testing, he added,
we trust that in reporting proceedings of the Lancashire and Cheshire Branch of the [BMA] ...you
will not omit from [your] report of Dr. Roberts’ paper that Kepler Malt Extract was mentioned first
on the list of articles he had found reliable and contained a proper amount of diastase. Other leading
medical journals with whom we have advertised less than with yourselves have been ready to give
me notice of our goods.
89
83Commissioner of Patents Journal,
11 Dec. 1877, p.1391.
84WFA, Acc82/1 Box 21, Chem. Drug.,
15 July 1879, 21: 23.
85WF/E/02/05/02,SMBurroughstoAlfredLewis,
4 March 1879.
86Chem. Drug., 15 Feb., 1879, 21: 63. The
formulae provided for 3 pints of spirit to 4 gallons
of malt, 3 pints glycerine, and 1 gallon cod
liver oil. Alcohol was substituted for spirit in
export orders.
87WF/E/02/05/02, S M Burroughs to Hayes & Co,
13 March 1879.
88Ibid.,SMBurroughstoeditorMedicalTimesand
Gazette, 2 May 1879.
89Ibid.
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Roy ChurchThe Lancet’s verdict was that KME could be used with confidence; the Medical Times and
Gazette placed the product first on the list of extracts of its kind because of its richness in
diastase and as a digester of starchy food. In 1879, Silas Burroughs referred to KME as
‘‘selling more than all the rest together’’, though no comparable data for SMB&Co or
BW&Co have survived. Sales by S M Burroughs & Co during its first year may have
reached £2,000.
90 Sales of Kepler to the value of £5,150 were recorded in 1879/80, of
£6,541 in 1880/1, and of £10,223 in 1881/1882. Trading profits of the Kepler enterprise
were £2,879, £3,480, and £5,046, an average return on sales of 53 per cent.
91
‘‘Detailing’’ Doctors, Chemists and Druggists: The Americanization
of Marketing Medicine in Britain
As sales expanded and agencies were added, Burroughs sought the support of another
who possessed experienceand skillscomparable tohisown. Itwas then that he approached
Henry Wellcome, also a former Philadelphia College pharmacy graduate, who had been
a detail man for the New York firm of McKesson & Robbins, drug manufacturers and
competitors of the Wyeths.
92 Burroughs invited Wellcome to join him, either as a manager
on a salary or as a partner.
93 Though Wellcome lacked financial resources, Burroughs
recognized the reputation which, at the age of twenty-seven, the young man already
enjoyed in the US, both for his knowledge of pharmacy and as a successful salesman.
These were valuable assets, as were his connections in the American trade, and explain the
lengthstowhichBurroughswaspreparedtogotobringhisownaspirationsforthebusiness
to fruition by enlisting the young American.
94 In August 1879, he wrote to Wellcome,
‘‘Think there is a big show for manufacturing Pharmaceutical Preparations and if we go
into it, it will be about the first in the field. Our house isthe only one inthe kingdom calling
on doctors with samples of new things’’.
95 Burroughs was also sanguine with respect to the
financial prospects. ‘‘You are the man I want to pull with,’’ he wrote to Wellcome in 1879,
‘‘and we have confidence in each other’s ability’’; and in early 1880, ‘‘Don’t fail to come.
I’m sure if you do and see the prospects here and look over our books you will stay.’’
96
The partnership of BW&Co commenced in September 1880. Even before it had been
legally confirmed, however, Wellcome’s value to the partnership was demonstrated at the
Cambridge meeting of the British Medical Association in August. Drawing on his
American experience where marketing methods were more advanced, his design of the
firm’s pharmaceutical exhibit attracted fulsome praise from the medical press.
97 Imagi-
native and spectacular exhibiting continued to be a feature of the partnership’s marketing
90This estimate is based on one month’s sales
figures quoted by Rhodes James, op. cit., note 9 above,
p. 75. No other data have been found.
91WF/E/02/05/02, S M Burroughs to editor
Medical Times and Gazette, 2 May 1879; WFA,
Acc99/6/7, KMEC balance sheets.
92Rhodes James, op. cit., note 9 above, pp. 61–4,
78–81.
93Ibid.,p.86.WFA,Acc89/72/01–4,AWJHaggis,
‘The life and work of Sir Henry Wellcome’
(unpublished typescript, 1942), p. 83,
quoting S M Burroughs to H Wellcome,
7 Feb. 1880.
94For a detailed account of the origins of the
partnership based on Wellcome’s correspondence,
see Rhodes James, op. cit., note 9 above, ch. 3.
95S M Burroughs to H Wellcome, Aug. 1879,
quoted in Haggis, op. cit., note 93 above, p. 80.
96S M Burroughs to H Wellcome, 20 Oct. 1879,
and early 1880, quoted in Haggis, ibid., p. 81.
97Rhodes James, op. cit., note 9 above,
pp. 89–90.
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The Innovative Impact of S M Burroughs & Copolicytosupportthe effortsoftravellers. Burroughs’smarketingphilosophywasdescribed
inponderousdetailinalettertoWellcomewrittenin1882,whileonhisoverseassalestour.
Salesmen,hebelieved,shouldemphasizetocustomersthatsellingtheproductswasintheir
own, as well as the partners’ interest, and that as a result of expanding the retailer’s sales
and profits, the supplier’s goods deserved to be pushed as thoroughly as the retailer’s
preparations.
98 Burroughs also advised on detailing doctors. In a note headed ‘Instructions
to travellers’, he emphasized the importance of calling on the retailer before the doctor
because the retailer could then be mentioned as an agent for the company, thereby increas-
ingthelikelihood ofhisreceiptofanorder.
99 Inthecase ofchemistswhodeclinedtoorder,
Burroughs advised that they should be persuaded to undertake to order the company’s
productsin future when prescribed by a doctor. This enabled the salesman to tell the doctor
that the drugs on the list were stocked by named chemists who were agents for the
company’s goods.
On the detailed logistics of enlisting the support of British doctors, Burroughs recom-
mended canvassing them while in hospital, rather than in their homes where they saw
private patients. This was because ‘‘The time of a London doctor which at hospital is
nothing to him is worth a guinea a minute’’ in private consulting rooms. Wellcome was
urgedto‘‘goforthehospitalsstrong’’,visitingforafewhoursduringafternoons,especially
when doctors and surgeons assembled in their private room to chat at the end of the day.
Burroughs had found doctors to be more likely to try novelties on hospital than on private
patients, partly because they hoped that reports of any tests they conducted might be
published. He also urged Wellcome to ‘‘get in with hospital surgeons and apothecaries’’
who would make appointments to see all the leading surgeons and others at convenient
hours.Finally,henoted that Formula Lists ofmedicalpreparations offered by the company
should be given to students and that he should ‘‘talk them up immensely’’.
100 Before the
first year of the partnership ended, Wellcome had begun to offer the benefit of his own
experience. He brought the agency of McKesson & Robbins’s sugar-coated pills into the
partnership and, inBurroughs’s absence in1881–83, implemented asystematic method for
researching the market and monitoring and reporting on salesmen’s performances, thus
building on the marketing strategy introduced to Britain by Burroughs.
A perceived conservatism of general practitioners tended to perpetuate traditional forms
ofmedicineanddiscouragedconnections withpharmaceuticalfirms.
101However,doctors’
responses to market surveys undertaken by BW&Co’s salesmen in 1881 and 1882, showed
them to have been favourably impressed by Wyeth’s compressed tablets and hypodermics,
Hazelinefacecream,Keplermaltextracts,andMcKesson’ssugar-coatedpills.Recourseto
prescriptionwaslesstime-consumingforbusygeneralpractitionersthannovelprocedures;
novel prescription medicines could demonstrate to patients that something practical was
being effected.
102 Orders for these goods may be interpreted as indicative of a profession
willing to receive visits from travellers for the first time and willing to accept samples of
98WF/M/GB/32/1, Records of travellers’
calls upon chemists and druggists at home and abroad,
1881–5, book 1.
99WFA, Acc87/33/69, ‘Instructions to
Travellers’.
100WFA, Acc87/33/2, S M Burroughs to
H Wellcome, 19 Jan. 1882.
101Digby, op. cit., note 5 above, p. 100.
102Ibid., p. 99.
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Roy Churchnew products, the two main features of the new method of marketing drugs. Either this
indicates a profession more receptive to innovation than has been portrayed hitherto, or it
is testimony to the effectiveness of the company’s travellers.
103 Compressed tablets (under
the Tabloid brand registered by BW&Co in 1884), Hazeline, and Kepler goods remained
the company’s leading brands well into the twentieth century.
Technical Innovation, Scientific Advance, and Transformation of the
Market for Medicine: Cause or Consequence?
The unparalleled scientific contribution to the foundation of a modern, laboratory-based
pharmaceutical industry in Britain by BW&Co (and specifically by Henry Wellcome)
between 1894 and 1914, has been well documented by E M Tansey and Rosemary
Milligan.
104 Less well known, and hitherto misinterpreted, are the contributions to the
Americanization of marketing in Britain before 1895, made by BW&Co, and especially by
its predecessor, SMB&Co. Although evidence relating to all pharmaceutical businesses at
this time is scarce, those comparisons which are possible provide some indication of the
source of the early commercial success of SMB&Co and of BW&Co. Although manu-
facturing and selling a similar range of products to those of Allen & Hanburys, including
proprietary goods (compressed medicines and cod liver oil and malt extract and infant
food), by 1892, BW&Co employed 600 workers.
105 This figure was not reached by Allen
& Hanburys until the First World War. Employees of BW&Co already exceeded 1,000 by
1901. By 1911, sales of £383,211 were recorded by Allen & Hanburys compared with
£575,756 for BW&Co.
106 The essential difference between the two companies (and other
competitors) before 1895 was marketing strategy.
Other firms were slow to emulate their methods until the twentieth century. In 1907, one
ofBW&Co’stravellersremarkedonthecontinuingpracticeofBritishfirmstoawaitorders
(delivered personally or by mail order). This essentially passive approach to the market,
he believed, placed BW&Co’s well-prepared travellers on the road in an advantageous
position to sell more effectively (thereby justifying higher salaries). He described the
typically passive role of drug house representatives in Britain as ‘‘wandering around
everythreemonthsintheordinarywayandhavingtheordershandedtothem’’.Hecontrasted
thisapproachwiththeproactiveengagementoftravellersworkingforBW&Cowhoreceived
regular briefings as to how to discuss with chemists the links between the company’s
103WF/M/GB/32/2, ‘Records of travellers’ calls
upon medical men at home & abroad, 1881–7’,
book 2, 26 Feb. 1883, 15 March 1883.
104E M Tansey and Rosemary C E Milligan,
‘The early history of Wellcome research laboratories,
1894–1914’, Wellcome Institute symposium on the
History of the Pharmaceutical Industry, Jan. 1987;
E M Tansey, ‘The Wellcome physiological research
laboratories, 1894–1904: the Home Office,
pharmaceutical firms, and animal experiments’,
Med. Hist., 1989, 33: 1–41.
105WFA, Acc82/1 Box 13, ‘Talk’ 21/7/1893.
106These exiguous comparisons were dictated by
the limited availability of data on pharmaceutical
firms, the exception being Tweedale, op. cit., note
78 above, pp. 115, 118; WFA Acc 96/45, BW&Co,
SalesBook2,p.1.BootsandBeechamswerealtogether
larger enterprises, but before 1911 these were
essentially patent and proprietary medicine
manufacturers, while Boots’ extensive retail
organization renders comparison even more irrelevant.
Among manufacturers of ethical pharmaceuticals,
BW&Co was almost certainly the largest.
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The Innovative Impact of S M Burroughs & Coproductsincludedonanewregularlyreviewed‘‘pushlist’’,totalkaboutthechemists’trade
and local dispensary practices, as well as how to interview medical practitioners.
107
Allen & Hanburys, for example, typically announced new developments in the medical
press, issued price lists, catalogues, and circulars. There is no evidence, however, that their
travellers visited surgeries or hospitals before 1911, though the company sometimes
distributed samples before the First World War. Mail orders continued to be important
in the 1920s.
108 When American pharmaceutical companies began to show interest in the
Canadian market, in 1905 the manager of Allen & Hanburys’ Canadian business com-
plained that they were destroying the company’s sales.
109 May & Baker’s first salesman
appears to have been appointed during the early 1890s (two were employed in 1894), but
there is no mention by the firm’s historian of detailing physicians.
110 The Nathan brothers
relied on heavy advertising and mail order to sell Glaxo products shortly before 1914,
although direct approaches were made to infant welfare centres and contacts established
with municipalauthorities.
111Glaxo employedtravellersbefore1929,thoughitshistorians
do not mention detailing.
112 Edgar Jones first refers to Glaxo representatives calling on
general practitioners from 1936 when the marketing strategy switched from ‘‘propaganda’’
toanethicalpolicy.
113Oftheremainingpharmaceuticalfirmslittle isknown,thoughthree,
T & H Morson & Son, Whiffen, and Howard were processors of raw materials for rapid
sale to wholesalers and manufacturers and did not require detailing. All were too small
to support more than a rudimentary laboratory.
114
Liebenau’s emphasis on the degree to which scientific developments affected medical
practice is exaggerated. Michael Worboys has shown that the scientific context within
which medicine was prescribed and sold was characterized by the existence of contra-
dictory ideas and ideals held by doctors, as well as extreme uncertainty regarding the
nature, causes, and treatment of disease.
115 The context of this debate was a prevailing
attitude amongdoctors thatitwasasimportanttobeawell-informedgentlemanpossessing
social skills and judgement, as it was to command technical expertise or medical knowl-
edge. Trial and error was the guiding basis of medical practice on which their living
depended.
116Forthisreason,someyoungerdoctorshopedtoimprovetheirmarketposition
by adopting new practices and therapies.
117 The picture painted by Worboys suggests that
the period between the 1870s and 1900 did not accord with the role reversal explained by
scientific advance identified by Liebenau.
107WFA, Acc82/1 Box 07, Proceedings of the
convention of home representatives, 1907, Curry, 71.
108Tweedale, op. cit., note 78 above, pp. 98,
103–4, 134–5.
109Wellcome Library, London, Lister Archives,
SA/Lis/I. 11fb, Lloyd Wood (Toronto) to Allen &
Hanburys (London), 22 May 1905.
110Judy Slinn, A history of May & Baker,
Cambridge, Hobsons, 1984, p. 57.
111R P T Davenport-Hines and Judy Slinn, Glaxo:
a history to 1962, Cambridge University Press, 1962,
pp. 38, 43–4.
112Ibid., p. 96.
113Edgar Jones, The business of medicine: the
extraordinaryhistoryofGlaxo,London,ProfileBooks,
2001, p. 52.
114Jonathan Liebenau, ‘Corporate structure and
researchanddevelopment’,inJonathanLiebenau(ed.),
The challenge of new technology: innovation in
British business, Aldershot, Gower, 1988, p. 35.
115Worboys, op. cit., note 22 above,
pp. 284–9.
116Lawrence, op. cit., note 22 above,
pp. 504–12.
117Worboys, op. cit., note 22 above, pp. 288–9.
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Roy ChurchLiebenau’s assessment of the role of BW&Co in transforming the marketing of drugs
between the 1890s and 1914 is also flawed. It is unsupported by evidence from the
Wellcome archives cited in support of the hypothesis because developments in the pre-
ceding period have been ignored.
118 Those historians who have focused on the BW&Co
partnership, and in particular on the role of Wellcome, have made valuable contributions
to the early history of the business and of the pharmaceutical industry in Britain.
119 This
limited focus, however, has obscured the preceding innovative role of Burroughs in the
evolution of the market for medicine. Archive sources relating to the history of SMB&Co
between 1878 and 1880, reveal Liebenau’s attribution of the marketing innovations to
Wellcome to be inaccurate as is the dating of their introduction to Britain.
120 His analysis
misinterprets their significance.
121
The history of marketing reveals only tenuous connections between the developments
in science and therapeutics in the mid-1890s and the innovations in marketing which
preceded the scientific and medical breakthrough by nearly twenty years. The trigger
which heralded the introduction of modern marketing was a hand-operated machine
which produced a qualitatively improved and lower cost pill, an improvement on the
products of the long discarded Brockedon machine, a British invention of 1843.
122
Rhodes James’s verdict on Burroughs, that he was ‘‘a superb salesman, not an innova-
tor’’,
123 displays a serious lack of appreciation, both of his development of a new market
in Britain for an innovative product and his introduction of the detailing approach to
marketing medicine.
Low, rather than high, technology, and a more efficient, though essentially cosme-
tically improved form of medicine, rather than therapeutic advance, explains the
Americanization of marketing in the British pharmaceutical industry before 1900. The
marketing transformation was driven by consumers rather than by science; doctors and
chemists needed to be persuaded of the advantages of compressed medicines and of the
new malt extracts. The successful resolution of this problem was the basis of BW& Co’s
rapid rise to become the largest pharmaceutical business in Britain. It preceded the
firm’s scientific leadership of the industry from the mid-1890s when it established
an enduring reputation rooted in advanced research. Applying the criterion of medical
progress, it is understandable that BW&Co has attracted most attention for those
achievements which emanated from the research laboratories. The laboratories were
unique in Britain and have been identified as the origins of the modern pharmaceutical
industry. Without the company’s trading success, however, the financial basis for Henry
Wellcome’s investment in research and development could not have occurred and the
establishment of a modern pharmaceutical industry in Britain would have been delayed.
In this respect, market success of the new biological therapeutics beginning in the 1890s
118Liebenau, ‘Marketing high technology’,
note 6 above, pp. 82–101.
119Tansey and Milligan, op. cit., note 104 above;
Tansey, op. cit., note 104 above; idem, op. cit.,
note 27 above, pp. 3–9; Rhodes James, op. cit.,
note 9 above.
120‘The ‘‘detail man’’ was introduced by
Wellcome’; Liebenau, op. cit., note 6 above,
p. 91.
121Tansey, op. cit., note 27 above, pp. 3–9.
122Rhodes James, op. cit., note 9 above,
pp. 77–8.
123Ibid., p. 78.
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The Innovative Impact of S M Burroughs & Coin Britain were a consequence rather than a cause of the marketing innovations
introduced by Silas Burroughs between 1878 and 1880.
124
124A business acquaintance referred to ‘‘initial
trade and national prejudice’’ because of the novel
character of his business and the unconventional
methods he adopted. ‘‘Burroughs made his own road
and it has become a highway’’, Chem. Drug.,
9 Feb. 1895, 46: 213. The marketing innovations
introduced by Silas Burroughs were not, of course, the
only ones affecting the growth in sales and profits
between 1880 and 1900 when the introduction of the
Tabloid brand, a supporting policy of litigation in its
defence, and the implementation of a resale price
maintenance policy were associated with Wellcome.
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